Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,643 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pancreatic Clear all
Terminated Phase 1 Interventional

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

NCT04152018
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer
Interventions
PF-06940434, PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Phase 1 Interventional

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

NCT06378047
View directory record Official record
Conditions
Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Interventions
Pembrolizumab, Irreversible Electroporation
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Phase 1 Interventional

A Study of ASN007 in Patients With Advanced Solid Tumors

NCT03415126
View directory record Official record
Conditions
Cancer, Malignancy, Neoplasia, Neoplasm, Neoplasm Metastasis, Colon Cancer, Colonic Neoplasms, Colon Cancer Liver Metastasis, Metastatic Cancer, Metastatic Melanoma, Metastatic Colon Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer Metastatic, Pancreatic Cancer, Pancreas Cancer, Pancreas Adenocarcinoma, Pancreas Neoplasm, Metastatic Nonsmall Cell Lung Cancer, Metastatic Pancreatic Cancer
Interventions
ASN007: ascending doses, ASN007 RD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 13, 2026, 4:07 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Not applicable Interventional

Whipple Protein Study

NCT04306874
View directory record Official record
Conditions
Pancreatic Cancer, Malnutrition
Interventions
Ensure Max Protein
Dietary Supplement
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 13, 2026, 4:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

NCT07539155
View directory record Official record
Conditions
Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer
Interventions
Intratumoral MMR Injection
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
Terminated Phase 3 Interventional

Management of Incidentally Discovered Pancreatic Cysts

NCT00550108
View directory record Official record
Conditions
Pancreatic Cyst
Interventions
Ethanol lavage
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2008 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

NCT02210559
View directory record Official record
Conditions
Pancreatic Cancer (Unresectable)
Interventions
FG-3019, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 13, 2026, 4:07 AM EDT
Recruiting Phase 1 Interventional

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

NCT07066657
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
MRG007, MRG007 and Bevacizumab
Drug
Lead sponsor
ArriVent BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders

NCT03775681
View directory record Official record
Conditions
Bile Duct Disorder, Endocrine Pancreas Disorder
Interventions
Endoscopic Retrograde Cholangiopancreatography, Interview, Laryngeal Mask Airway
Procedure · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 13, 2026, 4:07 AM EDT
Withdrawn Phase 1Phase 2 Interventional

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

NCT01600807
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic
Interventions
Gemcitabine, Erlotinib, OSI-906, Gemcitabine, Erlotinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 13, 2026, 4:07 AM EDT
Recruiting Not applicable Interventional

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

NCT05391126
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
Irinotecan
Drug
Lead sponsor
Reema A. Patel
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 13, 2026, 4:07 AM EDT
Terminated No phase listed Observational

Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy

NCT03407040
View directory record Official record
Conditions
Gastrointestinal Cancers, Breast Cancer, Pancreatic Cancer, Melanoma, Lung Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 13, 2026, 4:07 AM EDT
Terminated Phase 2 Interventional

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

NCT00116389
View directory record Official record
Conditions
Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
Interventions
talabostat mesylate tablets, gemcitabine
Drug
Lead sponsor
Point Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Florence, Alabama • Muscle Shoals, Alabama • Hartford, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2007 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT03777176
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Dasiglucagon, Standard of Care
Drug · Other
Lead sponsor
Zealand Pharma
Industry
Eligibility
3 Months to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 13, 2026, 4:07 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma

NCT00835133
View directory record Official record
Conditions
Familial Pancreatic Cancer
Interventions
biologic sample preservation procedure, medical chart review, survey administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
1,122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Phase 3 Interventional

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

NCT00026338
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 120 Years
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
74
States / cities
Tucson, Arizona • Springdale, Arkansas • Berkeley, California + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 13, 2026, 4:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

NCT07049055
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
El Segundo, California • Summit, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
Terminated No phase listed Observational

Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

NCT02113397
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TOBI™ Podhaler™ 112 mg inhaled twice daily, Colistimethate 75 mg inhaled two times daily
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
12 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 13, 2026, 4:07 AM EDT
Completed No phase listed Observational Results available

Advanced MRI Sequences for Radiation Therapy Treatment Planning

NCT02340715
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 89 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Sep 13, 2026, 4:07 AM EDT
Not listed Phase 1 Interventional

Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology

NCT03703089
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 13, 2026, 4:07 AM EDT
Active, not recruiting Phase 2 Interventional

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

NCT02955940
View directory record Official record
Conditions
Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
Interventions
Ruxolitinib, Capecitabine, Regorafenib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
6
States / cities
Santa Monica, California • Louisville, Kentucky • Clifton Park, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
No Longer Available No phase listed Expanded access

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

NCT01309022
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Sirolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Not applicable Interventional

A Pilot Study of a Low Glycemic Load Diet in Adults With Cystic Fibrosis

NCT04519853
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis With Intestinal Manifestations
Interventions
Low Glycemic Load Diet
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 13, 2026, 4:07 AM EDT